Central sleep apnea. Improvement with acetazolamide therapy

Area of Science:

• Sleep Medicine
• Respiratory Physiology
• Pharmacology

Background:

• Sleep apnea is linked to blood pH imbalances, with alkalosis potentially causing apneas.
• Acidification of blood may offer therapeutic benefits for certain sleep apnea types.

Purpose of the Study:

• To investigate the therapeutic effect of acetazolamide on symptomatic central sleep apnea.
• To assess the impact of acetazolamide-induced metabolic acidosis on respiratory drive.

Main Methods:

• Administered acetazolamide to six patients with central sleep apnea for one week.
• Conducted sleep studies before and after treatment to measure apnea frequency.
• Measured arterial pH and evaluated hypercapnic ventilatory response in normal subjects.

Main Results:

• A significant 69% reduction in total apneas was observed in all six patients.
• Five patients reported improved sleep quality and reduced daytime sleepiness.
• Acetazolamide therapy decreased mean arterial pH from 7.42 to 7.34.
• Acetazolamide shifted the hypercapnic ventilatory response to the left by 5 +/- 0.54 mm Hg.

Conclusions:

• Acetazolamide is an effective treatment for symptomatic central sleep apnea.
• Blood acidification via acetazolamide therapy improves respiratory control and reduces apneas.
• The observed improvements suggest a role for pH regulation in managing central sleep apnea.